Coastlands Capital LP bought 33,094 shares of Bolt Biotherapeutics, Inc. at $5.89 for $195k on Nov 16, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner
10%
Filed Nov 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$194,923.66Shares × reported price
Shares traded
33,094Common Stock
Price per share
$5.89Reported price. Read footnotes for ranges.
% of reported position traded
7.16%This security and ownership context
Holdings after
495,510Indirect · By Coastlands Capital LP
Trade date
Nov 16, 2026Buy
Filed
Nov 17, 2026, 8:42 PM ET2-day reporting delay
Accession
0001104659-26-129252Code P · Transaction 405095
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 462,416 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 17, 2026Buy20,000$5.75$114,998Trade 405096
2 transaction rows in this filing. Joint filers share the same rows.

BOLT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BOLT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 25, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −29%1w ago −27%1d ago +7.6%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $5.8000 to $5.9136. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the reporting persons will provide full information regarding the number of shares purchased at each separate price. F2: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.